July 31, 2021 11:39 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Kerala records 20,772 fresh COVID cases, state health minister says 'situation under control' | Both Indian men and women team register victories in Olympics hockey | Amid students' rush, Air India to increase flight frequency to US from August | Boxer Lovlina Borgohain ensured another medal for India from Tokyo Olympics. | OBC quota in medical colleges 'step taken late': BSP supremo Mayawati
Fight against COVID-19: Third phase of human trial of Covaxin to commence soon in IMS- SUM Hospital COVAXIN

Fight against COVID-19: Third phase of human trial of Covaxin to commence soon in IMS- SUM Hospital

India Blooms News Service | @indiablooms | 27 Oct 2020, 02:29 pm

Bhubaneswar/UNI: The third phase of the human trial of COVAXIN, the much-awaited indigenous vaccine being developed against Covid-19, will commence at the Institute of Medical Sciences and SUM Hospital here soon.

As the number of cases and deaths due to Covid- 19 continues to rise across the country, the battle against the disease through the search for a suitable vaccine has almost come to the final stage, Dr E. Venkata Rao, Principal Investigator in the COVAXIN human trial said.

Dr.Rao, a Professor in the Department of Community Medicine at IMS and SUM Hospital, said IMS and SUM Hospital is in the list of 21 medical institutes selected across the country by the Indian Council for Medical Research (ICMR) where the third phase trial would be conducted.

Sum Hospital is the only institute in Odisha which has been selected for the trial.

The indigenous vaccine, being developed by ICMR and Bharat Biotech, has received the approval of the Central Drugs Standard Control Organisation (CDSCO) for initiating the third phase trial.

Dr.Rao said after completion of the first and second phase of the trial with demonstrable safety profile and immunogenicity, the large scale efficacy trial involving thousands of volunteers has been planned

Dr Rao, who is the head of the Preventive and Therapeutic Clinical Trial Unit (PTCTU) at IMS and SUM Hospital, said during this phase the age limit and eligibility/ screening criteria would be relaxed and several volunteers who are otherwise apparently healthy would be recruited for the trial.

Like the previous phases, half of the volunteers would receive placebo and the remaining half would be administered COVAXIN in this phase.

Even health care workers would be recruited for the trial. The volunteers would be followed up over a considerable period of time to look at the efficacy of the vaccine in preventing the development of the Corona disease.

He said there had been a huge response and enthusiasm among people who had offered themselves to be volunteers for the trial.

The interested volunteers for the project could enroll themselves for the trial by registering online at www.ptctu.soa.ac under the section register for clinical trials, Dr Rao said.